Price$0.42+0.00 (+0.46%)
01:30 PM07:45 PM
News · 26 weeks36-22%
2025-12-142026-06-07
Mix1790d
- Other10(59%)
- SEC Filings6(35%)
- M&A1(6%)
Latest news
25 items- PRThree Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE BetIssued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP) A clinical-stage immuno-oncology company has moved three drug candidates into human testing over time --- and most recently expanded into solid tumors --- while carrying a market value that remains modest relative to many clinical-stage oncology peers. SAN FRANCISCO, June 08, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary -- Most clinical-stage cancer companies with three drugs that have reached human trials carry valuations in the hundreds of millions of dollars, or more. GT Biopharma, Inc. (NASDAQ:GTBP) has now advanced three TriKE® candidates into the clinic over time --- GTB-3550, GTB-3650 and GTB-5550 --- though its curr
- PRA Third Cancer Drug Just Entered the Clinic at an Under-$20-Million CompanyEquity Insider News CommentaryIssued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP)SAN FRANCISCO, June 2, 2026 /CNW/ -- Most clinical-stage cancer companies with three drugs dosing patients in human trials carry valuations in the hundreds of millions, or more. GT Biopharma, Inc. (NASDAQ:GTBP) recently put its third drug into the clinic — and the entire company has at times been valued at a small fraction of that. The gap between what the company is doing in the lab and what the market is paying for it is the whole story here, and a milestone reached in mid-May has brought it into sharp focus.
- PRGT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological InitiativesIncreased integration of artificial intelligence–based tools across the discovery and engineering of tumor-targeting engagers and multi-domain proteins to accelerate development while reducing developmental costs Reduces reliance on trial-and-error experimentation, shortens development timelines, and increases likelihood that pipeline candidates demonstrate robust binding and functional activity suitable for translational advancement GT Biopharma anticipates multiple new development candidates moving into pre-IND development in 2027, with potential targets and indications expanding beyond oncology SAN FRANCISCO, CALIFORNIA, June 01, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Comp
- PRThe $13 Million Company Teaching the Immune System to Hunt CancerIssued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP)Three drugs in human trials. A platform licensed from one of the world's top cancer-research universities. A market cap smaller than a Manhattan apartment. For investors willing to look where almost no one is looking, GT Biopharma is the kind of asymmetric setup that biotech is built on.NEW YORK, May 29, 2026 /CNW/ -- USA News Group Market Commentary - Start with the number that makes everyone do a double take. As of mid-May 2026, GT Biopharma (NASDAQ:GTBP) carried a market capitalization of roughly $13 million. Thirteen million. That is not a typo, and it is not a shell company. It is a clinical-stage immuno-oncology company with three sep
- SECGT Biopharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits8-K - GT Biopharma, Inc. (0000109657) (Filer)
- PRThree TriKE Candidates In Clinic As NK Cell Engager Field ReorganizesEquity Insider News CommentaryIssued on behalf of GT Biopharma, Inc.Companies mentioned: GT Biopharma, Inc. (NASDAQ:GTBP), Fate Therapeutics, Inc. (NASDAQ:FATE), Nkarta, Inc. (NASDAQ:NKTX), ImmunityBio, Inc. (NASDAQ:IBRX), INmune Bio, Inc. (NASDAQ:INMB)SAN FRANCISCO, May 19, 2026 /CNW/ -- The case for natural killer cell-based immunotherapy has been one of the longer-running theses in clinical oncology. NK cells sit on the body's first line of defense against foreign invaders, can be deployed as off-the-shelf therapeutics derived from donor cells or pluripotent stem cells, and have demonstrated meaningfully lower rates of cytokine release syndrome and graft-versus-host disease than the autol
- PRB7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters ClinicIssued on behalf of GT Biopharma, Inc. SAN FRANCISCO, May 18, 2026 /CNW/ -- USA News Group News Commentary — For more than two decades, B7-H3 sat on the shortlist of theoretically perfect cancer drug targets that nobody could quite figure out how to hit. The protein is broadly overexpressed across some of the most common — and most lethal — solid tumors, including prostate, lung, breast, ovarian, head and neck, and pancreatic cancers. It is largely absent from healthy tissue. It correlates with poor prognosis. On paper, it has every quality a drug developer wants. In practice, three B7-H3-targeting antibody-drug conjugates have entered the clinic, and none have yet been approved.[1] That is
- SECSEC Form 10-Q filed by GT Biopharma Inc.10-Q - GT Biopharma, Inc. (0000109657) (Filer)
- PRGT Biopharma Reports First Quarter 2026 Financial ResultsPhase 1 trial evaluating GTB-3650 TriKE® remains ongoing, with additional updates anticipated in 2H 2026 Phase 1 basket trial evaluating GTB-5550 TriKE® in multiple solid tumor types known to express B7-H3 initiated May 2026 with updates anticipated in 2H 2026 as enrollment progresses through dose escalation cohorts Cash balance as of March 31, 2026 of approximately $9 million anticipated to provide sufficient cash runway through Q4 2026 SAN FRANCISCO, CALIFORNIA, May 15, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) c
- PR"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming TherapiesIssued on behalf of GT Biopharma, Inc. After more than $1.7 billion in dealmaking and a string of Phase 1 starts in 2026, prostate, pancreatic, and other historically immunotherapy-resistant solid tumors are suddenly among the busiest battlegrounds in oncology — and a new natural killer cell engager just joined the field SAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- World Street Intelligence News Commentary — Until very recently, the immuno-oncology revolution had largely passed several of the most lethal solid tumor categories by. Checkpoint inhibitors, which transformed outcomes in melanoma, lung cancer, and renal cell carcinoma, have struggled to deliver meaningful benefit for the m
- PRA Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in OncologyIssued on behalf of GT Biopharma, Inc. From bispecific ADCs at IDEAYA to a GSK partnership at Summit, B7-H3 has become one of the most actively pursued antigens in solid tumor oncology — and a new natural killer cell engager just entered the clinic SAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary — For more than two decades, B7-H3 sat on the shortlist of theoretically perfect cancer drug targets that nobody could quite figure out how to hit. The protein is broadly overexpressed across some of the most common — and most lethal — solid tumors, including prostate, lung, breast, ovarian, head and neck, and pancreatic cancers. It is largely absent from healthy ti
- PRSolid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth PhaseMarket News Updates News Commentary Breakthrough immunotherapies, ADCs, and precision oncology platforms continue driving major investor attention across the global cancer treatment sectorNEW YORK, May 14, 2026 /CNW/ -- Momentum around solid tumor cancer treatments is picking up fast as new technologies and therapies continue delivering encouraging results across some of the hardest-to-treat cancers. From lung and breast cancer to colorectal, ovarian, and pancreatic cancers, drug developers are making real progress with next-generation immunotherapies, targeted treatments, and antibody-drug conjugates (ADCs). What's getting the industry excited is that many of these newer therapies are showi
- PRGT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid TumorsGTB-5550 is now the 3rd TriKE® to enter the clinic and an expansion into a broader solid tumor opportunity, with the Phase 1 trial likely to focus on prostate cancer patients during the dose escalation phase Company anticipates providing updates in 2H 2026 as enrollment progresses through dose escalation cohorts SAN FRANCISCO, CALIFORNIA, May 14, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced that the first patient was dosed in a Phase 1 dose escalation basket trial evaluatin
- SECSEC Form EFFECT filed by GT Biopharma Inc.EFFECT - GT Biopharma, Inc. (0000109657) (Filer)
- SECSEC Form 424B3 filed by GT Biopharma Inc.424B3 - GT Biopharma, Inc. (0000109657) (Filer)
- SECSEC Form S-1 filed by GT Biopharma Inc.S-1 - GT Biopharma, Inc. (0000109657) (Filer)
- SECGT Biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - GT Biopharma, Inc. (0000109657) (Filer)
- PRGT Biopharma to Participate in the 38th Annual Roth ConferenceSAN FRANCISCO, CALIFORNIA, March 11, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced that Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma, will participate in the 38th Annual Roth Conference being held March 22-24, 2026 in Laguna Niguel, CA. 38th Annual Roth Conference Format: Presentation and 1x1 investor meetingsPresentation Date: Tuesday, March 24th, 2026Time: 1:30 PM PDT The Company will be available for one-on-one meetings at the conference
- SECAmendment: SEC Form 10-Q/A filed by GT Biopharma Inc.10-Q/A - GT Biopharma, Inc. (0000109657) (Filer)
- SECAmendment: SEC Form 10-Q/A filed by GT Biopharma Inc.10-Q/A - GT Biopharma, Inc. (0000109657) (Filer)
- SECSEC Form 10-K filed by GT Biopharma Inc.10-K - GT Biopharma, Inc. (0000109657) (Filer)
- SECGT Biopharma Inc. filed SEC Form 8-K: Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Financial Statements and Exhibits8-K - GT Biopharma, Inc. (0000109657) (Filer)
- PRGT Biopharma Reports Full Year 2025 Financial ResultsPhase 1 trial evaluating GTB-3650 TriKE® continues to actively enroll, with the next update anticipated in Q3 2026 following completion of enrollment in dose Cohort 5 Phase 1 basket trial evaluating GTB-5550 TriKE® in multiple solid tumor types known to express B7-H3 remains on track to initiate mid-2026 Unaudited proforma cash balance as of January 31, 2026 of approximately $9 million anticipated to provide sufficient cash runway through Q4 2026 SAN FRANCISCO, CALIFORNIA, March 02, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural ki
- PRGT Biopharma to Present at the Centurion One Capital 9th Annual Toronto Growth ConferenceSAN FRANCISCO, CALIFORNIA, Feb. 17, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced that Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma, will be participating in the Centurion One Capital 9th Annual Toronto Growth Conference on Thursday, March 5th, 2026, in Toronto, Ontario. Centurion One Capital 9th Annual Toronto Growth Conference Format: Presentation, panel discussion and 1x1 investor meetingsPresentation Date: Thursday, March 5th, 2026Time: 8
- PRGT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3GTB-5550 Phase 1 dose escalation basket trial expected to initiate mid-2026 Phase 1 protocol allows multiple solid tumor types known to express B7-H3 Unaudited proforma cash balance as of January 31, 2026 of approximately $9 million anticipated to extend cash runway through Q4 2026 SAN FRANCISCO, CALIFORNIA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced FDA clearance of its IND application for GTB-5550, allowing the company to proceed with a Phase 1 clinical trial,
GTBP FAQ
6 questionsWhat does GT Biopharma Inc. do?
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. The company develops various immuno-oncology product candidates, including GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and other CD33+...Where does GTBP stock trade?
GT Biopharma Inc. (GTBP) is listed on NASDAQ.What sector and industry is GTBP in?
GT Biopharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about GTBP?
GT Biopharma Inc. has had 1 recent analyst action on file. The most recent action was from ROTH MKM: Buy with a $1100.00 price target on 2024-12-02. Recent price targets cluster around $1100.00.What companies are similar to GTBP?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare GTBP side-by-side with any of them on Quantisnow.How can I track GTBP on Quantisnow?
Quantisnow aggregates GT Biopharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GTBP to receive live email and push alerts on every new disclosure.